cell therapy
-
The “Hidden Reasons” Behind WuXi AppTec’s Sale of CGT Business
It is believed that both WuXi AppTec and WuXi ATU will continue to exert greater energy for more innovators and patients in need in the future
-
Gene editing therapy bombshell: A trial participant has died
many analysts are positive about Beam’s future
-
Stock prices soar by 220%! CGT, once “unsellable,” is back in the spotlight
If you are intersted in TCR-T, you are welcome to watch DrugTimes webinar tonight
-
【ASCO Highlights】China-made First-in-Class Claudin 18.2 CAR-T Therapy Shows Promising Phase I Results!
Follow Drug Times to grasp valuable industry information at the first moment
